Drug Therapy Protocols: Atropine

<table>
<thead>
<tr>
<th>Policy code</th>
<th>DTP_ATR_0519</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date</td>
<td>May, 2019</td>
</tr>
<tr>
<td>Purpose</td>
<td>To ensure a consistent procedural approach to atropine administration.</td>
</tr>
<tr>
<td>Scope</td>
<td>Applies to Queensland Ambulance Service (QAS) clinical staff.</td>
</tr>
<tr>
<td>Health care setting</td>
<td>Pre-hospital assessment and treatment.</td>
</tr>
<tr>
<td>Population</td>
<td>Applies to all ages unless stated otherwise.</td>
</tr>
<tr>
<td>Source of funding</td>
<td>Internal – 100%</td>
</tr>
<tr>
<td>Author</td>
<td>Clinical Quality &amp; Patient Safety Unit, QAS</td>
</tr>
<tr>
<td>Review date</td>
<td>May, 2022</td>
</tr>
</tbody>
</table>

While the QAS has attempted to contact all copyright owners, this has not always been possible. The QAS would welcome notification from any copyright holder who has been omitted or incorrectly acknowledged.

All feedback and suggestions are welcome. Please forward to: Clinical.Guidelines@ambulance.qld.gov.au

Disclaimer

The Digital Clinical Practice Manual is expressly intended for use by QAS paramedics when performing duties and delivering ambulance services for, and on behalf of, the QAS.

The QAS disclaims, to the maximum extent permitted by law, all responsibility and all liability (including without limitation, liability in negligence) for all expenses, losses, damages and costs incurred for any reason associated with the use of this manual, including the materials within or referred to throughout this document being in any way inaccurate, out of context, incomplete or unavailable.


This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives V4.0 International License

You are free to copy and communicate the work in its current form for non-commercial purposes, as long as you attribute the State of Queensland, Queensland Ambulance Service and comply with the licence terms. If you alter the work, you may not share or distribute the modified work. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/deed.en

For copyright permissions beyond the scope of this license please contact: Clinical.Guidelines@ambulance.qld.gov.au
**Drug class**
Anticholinergic (antimuscarinic)

**Pharmacology**
Atropine works by inhibiting the action of the parasympathetic nervous system allowing for an unchallenged sympathetic response. It successfully blocks the action of the vagus nerve on the heart, increases the rate of the SA node, conduction through the AV node and blocks exocrine gland activity.[1-3]

**Metabolism**
Atropine is metabolised by the liver and excreted mainly by the kidneys.[1-3]

**Indications**
- Bradycardia (with poor perfusion)[4]
- Envenomation (with increased parasympathetic activity)
- Hypersalivation (secondary to ketamine administration)
- Organophosphate toxicity (with cardiac AND/OR respiratory compromise)[5]

**Contraindications**
- Allergy and/or Adverse Drug Reaction

**Precautions**
- Atrial flutter
- Atrial fibrillation
- AMI
- Glaucoma

**Side effects**
- Agitation
- Hallucinations
- Dilated pupils
- Dry mouth/dry skin/reduced bronchial and gastric secretions
- Tachycardia

**Presentation**
- Ampoule, 1.2 mg/1 mL atropine sulphate monohydrate

**Onset (IV)**
1–2 minutes (peak 15–50 minutes)

**Duration (IV)**
Up to 5 hours

**Half-life**
3–4 hours
Atropine

Schedule

- S4 (Restricted drugs).

Routes of administration

- Intramuscular injection (IM)
- Intravenous injection (IV)
- Intraosseous injection (IO)
- Intravenous infusion (IV INF)

Special notes

- A dose of up to 1.2 mg of atropine is generally sufficient to resolve bradycardia in adult patients. Subsequent doses in patients who fail to respond is not usually beneficial.[5]
- Sub-therapeutic doses of atropine may cause paradoxical bradycardia.

Special notes (cont.)

- Ambulance officers must only administer medications for the listed indications and dosing range. Any consideration for treatment outside the listed scope of practice requires mandatory approval via the QAS Clinical Consult and Advice Line.
- Atropine requirements for organophosphate toxicity vary enormously between patients and organophosphates.
- Target atropinisation for organophosphate toxicity is achieved when the patient has the following endpoints:
  - chest clear and no wheeze on auscultation
  - heart rate > 80 beats per minute
  - systolic BP > 80 mmHg
- Organophosphate toxicity induced tachycardia should not prohibit atropine administration if respiratory distress is present (e.g. profuse oral and/or bronchial secretions).
- Total loading dose (CCP ESoP – aeromedical IV INF protocol) is defined as the sum of the initial doses given at the beginning of a course of treatment prior to administering a lower maintenance dose.
- Atropine administration is not indicated in the newly born pre-hospital resuscitation.
- All cannulae and IV lines must be flushed thoroughly with sodium chloride 0.9% following each medication administration.
**Adult dosages**

**Bradycardia (with poor perfusion)**

<table>
<thead>
<tr>
<th>Route</th>
<th>Dose</th>
<th>Administration</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>IV</td>
<td>600 microg</td>
<td>Repeated once after 2 minutes.</td>
<td>Total maximum dose 1.2 mg.</td>
</tr>
<tr>
<td>IO</td>
<td>600 microg</td>
<td>Repeated once after 2 minutes.</td>
<td>Total maximum dose 1.2 mg.</td>
</tr>
</tbody>
</table>

**Envenomation (with increased parasympathetic activity)**

<table>
<thead>
<tr>
<th>Route</th>
<th>Dose</th>
<th>Administration</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>IM</td>
<td>1.2 mg</td>
<td>Repeated at 5 minute intervals.</td>
<td>No maximum dose.</td>
</tr>
<tr>
<td>IV</td>
<td>1.2 mg</td>
<td>Repeated at 5 minute intervals.</td>
<td>No maximum dose.</td>
</tr>
<tr>
<td>IO</td>
<td>1.2 mg</td>
<td>Repeated at 5 minute intervals.</td>
<td>No maximum dose.</td>
</tr>
</tbody>
</table>

**Hypersalivation (secondary to ketamine administration)**

<table>
<thead>
<tr>
<th>Route</th>
<th>Dose</th>
<th>Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>IV</td>
<td>600 microg</td>
<td>Single dose only.</td>
</tr>
</tbody>
</table>

**Organophosphate toxicity (with cardiac AND/OR respiratory compromise)**

<table>
<thead>
<tr>
<th>Route</th>
<th>Dose</th>
<th>Administration</th>
<th>Maximum Dose</th>
</tr>
</thead>
<tbody>
<tr>
<td>IM</td>
<td>1.2 mg</td>
<td>Repeated at 5 minute intervals.</td>
<td>No maximum dose.</td>
</tr>
<tr>
<td>IV</td>
<td>1.2 mg</td>
<td>Repeated at 5 minute intervals.</td>
<td>No maximum dose.</td>
</tr>
<tr>
<td>IO</td>
<td>1.2 mg</td>
<td>Repeated every 5 minutes.</td>
<td>No maximum dose.</td>
</tr>
</tbody>
</table>

RSQ Clinical Coordinator consultation and approval required in all situations.

5–10 mL/hour (10–20% of leading dose/hour) to maintain atropinisation.

**Syringe preparation:** Mix the total loading dose of atropine with sodium chloride 0.9% to make up a total volume of 50 mL. Ensure all syringes are appropriately labelled.
### Paediatric dosages

<table>
<thead>
<tr>
<th>Bradycardia (with poor perfusion)</th>
</tr>
</thead>
</table>
| **IV** | 20 microg/kg  
Single dose not to exceed 600 microg.  
Repeated once after 2 minutes.  
Total maximum dose 40 microg/kg. |
| **IO** | 20 microg/kg  
Single dose not to exceed 600 microg.  
Repeated once after 2 minutes.  
Total maximum dose 40 microg/kg. |

- **Envenomation** (with increased parasympathetic activity)
- **Organophosphate toxicity** (with cardiac AND/OR respiratory compromise)

| **IM** | 20 microg/kg  
Single dose does not exceed 600 mg.  
Repeated at 5 minute intervals.  
No maximum dose. |
| **IV** | 20 microg/kg  
Single dose does not exceed 600 mg.  
Repeated at 5 minute intervals.  
No maximum dose. |
| **IO** | 20 microg/kg  
Single dose not to exceed 600 microg.  
Repeated at 5 minute intervals.  
No maximum dose. |

### Paediatric dosages (cont.)

<table>
<thead>
<tr>
<th>Hypersalivation (secondary to ketamine administration)</th>
</tr>
</thead>
</table>
| **IV** | 20 microg/kg  
Single dose not to exceed 600 mcg.  
Single dose only. |